Copyright: ©Author(s) 2026.
World J Cardiol. Aug 26, 2026; 18(8): 124876
Published online Aug 26, 2026. doi: 10.4330/wjc.124876
Published online Aug 26, 2026. doi: 10.4330/wjc.124876
| Aging mechanism or biomarker category | Representative biomarkers or pathways | Sample and assessment method | Potential clinical or cardiovascular relevance | Ref. |
| DNA damage and telomere attrition | γ-H2AX, 8-oxo-dG, telomere length | Immunofluorescence, comet assay, qPCR in leukocytes | DNA damage and telomere shortening induce EC and VSMC senescence, accelerating atherosclerosis and myocardial aging | Blackburn et al[32]; Deng et al[33]; Li et al[34]; Bloom et al[41] |
| Mitochondrial dysfunction and oxidative stress | mtROS, SIRT3/PGC-1α, ATP loss | Seahorse assay, ROS probes, WB | Excess mtROS triggers vascular inflammation and cardiac fibrosis; restoring SIRT3 improves endothelial function | Dai et al[22]; Goodman et al[23]; Dai et al[24]; Bachschmid et al[40]; Bloom et al[41]; Mondragon et al[49] |
| Nutrient sensing imbalance (mTOR/AMPK/SIRT axis) | mTOR, AMPK, SIRT1 | WB, phosphoprotein analysis | Overactive mTOR and low SIRT1/AMPK promote metabolic inflammation, endothelial dysfunction, and cardiac hypertrophy | Zhan et al[46]; Fontana et al[88]; Qu et al[89]; Justice et al[96]; Greenberg et al[97]; Zhang et al[99] |
| Cellular senescence and SASP secretion | p16INK4a, p21CIP1, SA-β-gal, IL-6/IL-1β/TNF-α (SASP) | qPCR, IHC, ELISA | Senescent ECs and VSMCs release SASP, chronic inflammation, plaque instability and impaired repair | Di Micco et al[9]; Gorgoulis et al[12]; Owens et al[15]; Mehdizadeh et al[16]; Wang et al[18]; Honda et al[19]; Garrido et al[94]; Karnewar et al[95] |
| Clonal hematopoiesis of indeterminate potential | DNMT3A, TET2, ASXL1, JAK2 mutations; VAF ≥ 2% | Targeted DNA sequencing (NGS) in peripheral blood | Identifies an age-related hematopoietic state associated with atherosclerotic CVD, heart failure, arrhythmias, and valvular disease | Jaiswal et al[111]; Tan et al[112] |
| Stem cell exhaustion and impaired regeneration | CD34+ EPCs, c-Kit+ cardiac progenitors | Flow cytometry, colony forming assay | Reduced progenitor pool limits endothelial repair and neovascularization in aging hearts and vessels | Mehdizadeh et al[16]; Sorokina et al[75] |
| Inflammaging and immune dysregulation | CRP, IL-6, NLRP3 inflammasome activation | ELISA, transcriptomics | Low-grade systemic inflammation drives endothelial activation and cardiac fibrosis; IL-1β blockade reduces events in elderly | Khalafi et al[56]; Müller and Di Benedetto[57]; Danesh et al[58]; Zhou et al[59]; Thompson and Nidorf[92]; Tardif et al[93] |
| Altered intercellular communication (exosomes/SASP spread) | Exosomal miR-21/miR-126, NF-κB, NLRP3 | Nanoparticle tracking, qPCR, WB | Senescent cell-derived exosomes propagate inflammatory signals and fibrotic remodeling across cardiac tissues | Acosta et al[10]; Admasu et al[11]; Gorgoulis et al[12] |
| Extracellular vesicles | EV surface antigens (EV aging index); endothelial micro-vesicles (EMVs: | Nanoparticle tracking, flow cytometry, ELISA in serum/plasma | EVs mediate endothelial dysfunction and senescence-associated vascular dysfunction; EMVs increase with age and correlate with endothelial vasodilator dysfunction; EV aging index stratifies CV risk | Burrello et al[80]; DeSouza et al[113] |
| Epigenetic aging biomarkers | Horvath clock, Hannum clock, PhenoAge, GrimAge, epigenetic age acceleration | DNA methylation arrays or sequencing in peripheral blood | Quantify biological age and age acceleration; associated with subclinical atherosclerosis, arterial stiffness, heart failure, and cardiovascular mortality | Allegra et al[27]; Sánchez-Cabo et al[28]; Chen et al[29]; Fox et al[30]; Joyce et al[31]; Yamada[81]; Hannum et al[82]; Horvath[83]; Ammous et al[84]; Feng et al[85] |
| Proteomic aging clocks | Multi-marker protein panels, including 204-protein and organ-specific proteomic age scores | Olink, SomaScan, or mass-spectrometry-based plasma proteomics | Estimate systemic and organ-specific biological age and predict incident cardiovascular disease, multimorbidity, and mortality | Argentieri et al[114]; Robinson et al[115] |
| Metabolomic and lipidomic aging scores | MetaboPhenoAge; lipidomic metabolic age score | Mass spectrometry or NMR spectroscopy in plasma or serum | Capture metabolic aging and may predict incident cardiovascular disease and cardiometabolic risk beyond chronological age | You et al[116]; Wang et al[117] |
| Circulating inflammatory and myocardial stress biomarkers | hsCRP, IL-6, TNF-α, GDF-15, sST2, galectin-3, NT-proBNP, hs-cTn | ELISA, immunoassay, serum or plasma | Reflect inflammaging, myocardial stress, fibrosis, and subclinical cardiovascular injury; may support risk stratification in older adults | Giovannini et al[73]; Oppong et al[76]; Parikh et al[77]; Keng et al[78] |
| Circulating microRNAs | miR-23a-3p, miR-92a-3p, and other age-associated microRNAs | qPCR, small-RNA sequencing in plasma or serum | May reflect vascular inflammation, endothelial dysfunction, and cardiovascular risk in older adults | La Grotta et al[79] |
- Citation: Liu Q, Wang YF, Geng Y, Zhang P, Lv TT. Cardiovascular aging as a modifiable biological process: Mechanisms, clinical phenotypes, and translational opportunities. World J Cardiol 2026; 18(8): 124876
- URL: https://www.wjgnet.com/1949-8462/full/v18/i8/124876.htm
- DOI: https://dx.doi.org/10.4330/wjc.124876